OOIR: Observatory of International Research

Papers

(The median citation count of Molecular Therapy-Oncolytics is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	238
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	79
Ferroptosis gene signature in cholangiocarcinoma	55
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	46
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	44
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	43
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	38
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	36
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	36
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	33
PROTACs in gastrointestinal cancers	33
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	33
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	32
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	32
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	31
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T	30
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response	30
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity	30
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	29
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia	29
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	29
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia	28
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges	27
Adding recombinant AAVs to the cancer therapeutics mix	26
Radiovirotherapy at twenty	26

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products	26
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis	25
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum	25
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma	24
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression	24
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice	24
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis	23
Oncolytic adenovirus for treatment of malignant ascites	23
DNA-damaging cancer cells to improve virotherapy	23
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?	23
Thank you to our 2023 reviewers	22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities	22
Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene	21
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells	21
Non-coding RNAs and glioma: Focus on cancer stem cells	21
Sodium iodide symporter-targeted gene therapy in glioblastoma	21
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers	21
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response	20
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo	20
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon	20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape	19
Exploring the potential of eRNAs in cancer immunotherapy	19
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy	19
Advancing together and moving forward: Combination gene and cellular immunotherapies	19
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering	19
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution	19
Comprehensive landscape of tRNA-derived fragments in lung cancer	18
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives	18
Gaining insights into virotherapy with canine models	18
Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer	17
Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors	17
A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase	17
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells	17
Advancements in CRISPR screens for the development of cancer immunotherapy strategies	17
miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration	17
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project	17
The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics	17
Targeting mesothelin in cancer	17
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer	17
Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites	17
Retraction Notice to: miR-140-3p Inhibits Cutaneous Melanoma Progression by Disrupting AKT/p70S6K and JNK Pathways through ABHD2	16
Expanding the landscape of TCR gene therapy targeting MAGE	16
Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies	16
A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics	16
Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma	16
Novel roles of METTL1/WDR4 in tumor via m7G methylation	15
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer	15
PTEN potentiation of oncolytic HSV therapy for glioblastoma	15
Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime	15
PBX3-activated DLG1-AS1 can promote the proliferation, invasion, and migration of TNBC cells by sponging miR-16-5p	15

Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition	14
Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation	14
Oncolytic viruses: Narcissistic or altruistic arsonists?	14
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	14
CRISPR-Cas knockout of miR21 reduces glioma growth	14
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions	14
LncRNA CBR3-AS1 promotes osteosarcoma progression through the network of miR-140-5p/DDX54-NUCKS1-mTOR signaling pathway	14
Attack of the clones: An NK cell origins story	14
An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition	13
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors	13
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10	13
Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors	13
Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2	13
Dynamic fine-tuning of CAR-T cell therapy	12
Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody	12
Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model	12
Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models	12
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives	12
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9	12
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities	12
Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer	12
TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I	11
The tRNA-derived fragment signature in lung cancer	11
Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models	11
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors	11
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma	11
Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma	11